Direct-acting Antiviral Retreatment Patterns for Hepatitis C

Despite the strong efficacy of direct-acting antivirals (DAAs) against the hepatitis C virus, many patients require a second regimen of DAA treatment. However, limited research exists to characterize rates of retreatment across different DAA agents or potential factors that may increase retreatment risk. To characterize patterns and predictors of DAA retreatment among a large, generalizable, commercially insured US population of patients. Using the IBM MarketScan Commercial Claims and Encounters data source, this retrospective cohort study examined retreatment patterns among patients receiving DAAs between 2013 and 2019. Descriptive statistics were used to compare patient characteristics predictive of retreatment risk and to examine rates of retreatment in patients initiating different DAA treatments. Among 31,553 DAA users, a total of 1,017 (3.2%) required DAA retreatment. Among the 1,017 patients re-treated, 44 (4.3%) received a third treatment regimen and 2 patients received a fourth treatment regimen. The average total cost for a retreatment regimen was $109,683, with patient out-of-pocket costs totaling $1,287 Patients requiring retreatment had higher rates of hypertension (32.0% vs 26.7%; < 0.001), diabetes (16.9% vs 11.9%; < 0.001), coagulopathy (9.9% vs 4.5%; < 0.001), deficiency anemia (11.1% vs 7.4%; < 0.001), alcohol abuse (3.3% vs 2.3%; = 0.038), prior liver transplantation (3.4% vs 2.3%; = 0.024), and hepatocellular carcinoma (6.1% vs 1.9%; < 0.001) compared with patients not requiring retreatment. Although uncommon, some patients receiving DAAs require a second regimen of DAA treatment at substantial cost to both health plans and patients. These patients tend to have more comorbidities and markers of hepatic disease severity. Patients with high retreatment risk may benefit from careful monitoring for occurrences of retreatment.